Skip to content

Company

About us

GATC Health transforms the way drugs are created, developed, and financed. Verified at 91% specificity and 86% sensitivity, and trusted by the world’s largest insurance marketplace, our Operon™ platform creates innovative therapeutic solutions, extends pipelines, and optimizes assets. Like a FICO® Score for drug discovery and development, our Derisq™ AI Report delivers objective, Operon-powered insights that help biopharma leaders and investors prioritize assets and predict outcomes – all before committing capital or entering the clinic.

The Minds Behind the Innovation

GATC Health brings together the industry’s leading experts in AI, biology, drug development, and business strategy. With collective decades of hands-on experience, we take an objective, pragmatic view of drug candidates and work closely with you, shaping strategy and pressure-testing results to help you bring better therapies to patients, faster.

John Stroh

Chief Executive Officer
John Stroh headshot

John Stroh

Chief Executive Officer

  • Executive roles in Life Sciences, Biotech, and Pharma involving leadership in investment banking, M&A and strategic partnerships.

  • $18 billion in financing while at Roth Capital Partners, Piper-Jaffray and John Nuveen & Co.

  • Management positions at Boustead Securities, Nanospectra Biosciences, Kadmus Pharmaceuticals, Global Healthcare Advisors,  Neomatrix, Merck, and Atairgin Medical.

Jayson Uffens

Chief Technology Officer, Chairman
Jayson Uffens headshot

Jayson Uffens

Chief Technology Officer, Chairman

  • 20+ years in start-ups, rapid growth, & enterprise companies

  • CEO Fintech AI start-up

  • GrubHub/Seamless – VP Engineering

  • Solution Director – Acquity Group

  • Director / Architect – GoDaddy

Dr. Rahul Gupta

President
Dr. Rahul Gupta headshot

Dr. Rahul Gupta

President

  • Dr. Rahul Gupta was the first physician to lead the White House Office of National Drug Control Policy (2021–2025), overseeing a $44 billion budget across 19 agencies.

  • He is credited with historic progress in reducing U.S. drug overdose deaths, saving hundreds of thousands of lives.

  • With 25+ years in primary care, he also served as West Virginia Health Commissioner and led innovative public health collaborations.

  • Gupta has held academic roles at Georgetown and Harvard, and advanced global health as Chief Medical Officer at March of Dimes.

Ian Jenkins

Chief Science Officer
Ian Jenkins headshot

Ian Jenkins

Chief Science Officer

  • Unprescribed – CoFounder – Computational Predictive Genetic Expression

  • Orn – Junior VP –  Clinical Development for Precision Medicine

  • Davidson Lab – Laboratory Scientist – Epigenetic Research

  • Midwestern – Laboratory Scientist – Genetics Research

Vaishnavi Narayan

Head of AI Engineering
Vaishnavi Narayan headshot

Vaishnavi Narayan

Head of AI Engineering

  • Co-developer of GATC Health’s foundational AI technology

  • IBM / IBM Watson – Associate Engineer

  • Frelii – Sr Machine Learning Engineer for deep learning models for drug activity prediction

  • Brigham Young University – Graduate Research Assistant, Deep Learning for Healthcare

Tyrone Lam

Chief Business Development Officer
Tyrone Lam headshot

Tyrone Lam

Chief Business Development Officer

  • First Americans Wellness – Co-founder & COO

  • OneRecovery/OneHealth (purchase by Viverae/SimplyWell) – Co-founder

  • NTN Buzztime (publicly traded) – President & COO

  • Predilytics (purchased by Welltok) – VP Business Development

Eric J. Mathur

Chief Innovation Officer
Eric J. Mathur headshot

Eric J. Mathur

Chief Innovation Officer

  • TLIT Holdings, Yulex Corporation, Synthetic Genomics, Diversa Corporation

  • Internationally recognized expert in genome sciences, molecular biology, microbiology

  • Named inventor on >150 patents; 50+ peer reviewed publications with >8,000 citations

Megan Bradshaw

Director of People & Culture
Megan Bradshaw  headshot

Megan Bradshaw

Director of People & Culture

  • Over a decade of experience supporting founders and executive teams across fast-growing startups, with a proven record of scaling people operations and company culture.
  • Extensive background spanning HR, office management, executive assistance, investor relations, and accounting—bringing a unique 360° understanding of startup operations.
  • Seasoned people leader known for building strong organizational foundations, aligning culture initiatives with business goals, and fostering employee engagement during rapid growth.
  • Trusted partner to leadership, combining operational precision with strategic people management to drive performance, retention, and organizational excellence.

Eugene O’Bryan

Chief Operations Officer
Eugene O’Bryan headshot

Eugene O’Bryan

Chief Operations Officer

  • 30+ years C-Level Banking & Financial Service Executive with a focus on Strategic Planning, Business Development, & Operation Management 

  • COO for NYSE bank holding company, lead $60M IPO to $1.8B valuation

  • President/COO of PE backed regional lender that grew to a top 30 national lending institution with a $750M valuation

Jeff Moses

Chief Compliance Officer
Jeff Moses headshot

Jeff Moses

Chief Compliance Officer

  • PowerOne Energy Corp – Co-founder, CMO, Director

  • Multiple C-level positions with growth stage companies

  • Founder & creative director of ad agency serving Fortune 500 clients

Robert Tinder, PhD

Head of Chemical Research and Development
Robert Tinder, PhD headshot

Robert Tinder, PhD

Head of Chemical Research and Development

  • More than 15 year experience in drug discovery

  • Former Scientist at Pfizer, Roche and Ionis Pharmaceuticals

  • Expert in Continuous Manufacturing as well as Process Research and Development

  • Serial Entrepreneur Having Co-Founded 3 startups

Waldemar Lernhardt, PhD

Vice President of Scientific Operations
Waldemar Lernhardt, PhD headshot

Waldemar Lernhardt, PhD

Vice President of Scientific Operations

  • ProSci, Inc. – Chief Operations Officer

  • ReadiX GmbH – Chief Science Officer

  • Proveri Inc. – President/CEO

  • Therapeutics, Inc. – VP Product Development

Mark Flather

Senior Vice President, Business Development and Strategy
Mark Flather headshot

Mark Flather

Senior Vice President, Business Development and Strategy

  • Mark Flather is Senior Vice President, Business Development and Strategy at GATC Health, joining the company in January 2026.
  • He previously served as Senior Vice President of Corporate Strategy and Capital Markets at Vistagen Therapeutics, a late-stage biopharmaceutical firm focused on CNS therapeutics.
  • With over 30 years of capital markets experience, Flather has held senior roles in investor relations, corporate communications, and equity trading across multiple healthcare and finance organizations.
  • His past positions include leadership roles at Adamis Pharmaceuticals, MZ Group, Hermes Advisors, and Alex. Brown & Sons

Advisors

Our board of advisors is a powerhouse of knowledge and experience. Comprising esteemed researchers, medical doctors, biotech executives, and policy experts, they offer invaluable guidance in steering GATC’s mission.

Herbert Boyer

Herbert Boyer

Herbert Boyer headshot

Herbert Boyer

  • Co-founded Genentech (first biotech company to go public)
  • Co-discovered methods that founded genetic engineering
  • Numerous awards including the Albert Lasker Award for Medical Research, Industrial Research Institute Achievement Award, the National Medal of Technology, National Medal of Science
Dr. Tomas Philipson 

Dr. Tomas Philipson 

Dr. Tomas Philipson  headshot

Dr. Tomas Philipson 

  • Former Acting Chairman, U.S. Council of Economic Advisers 
  • Daniel Levin Chair in Public Policy, University of Chicago Internationally recognized health economist and frequent contributor to Forbes and major media outlets 
  • Internationally recognized health economist and frequent contributor to Forbes and major media outlets 
  • Ph.D. in Economics, University of Pennsylvania 

Dr. Richard Schatz

Dr. Richard Schatz

Dr. Richard Schatz headshot

Dr. Richard Schatz

  • Research Director of Cardiovascular Interventions, Scripps Heart, Lung & Vascular Center 
  • Co-inventor of the Palmaz-Schatz Coronary Stent, revolutionizing treatment for coronary artery disease 
  • Recipient of the Russ Prize for Bioengineering and inductee of the National Inventors Hall of Fame 

Johnathan Lakey, PhD, MSM

Johnathan Lakey, PhD, MSM

Johnathan Lakey, PhD, MSM headshot

Johnathan Lakey, PhD, MSM

  • Professor Emeritus, Surgery & Biomedical Engineering, UC Irvine School of Medicine
  • Adjunct Professor, WVU Medicine
  • Diabetes and islet transplantation expert, Edmonton Protocol co-developer
  • International Speaker on islet transplantation, stem cell research and diabetes
  • 500+ authored scientific papers

Dr. Lin Yu

Dr. Lin Yu

Dr. Lin Yu headshot

Dr. Lin Yu

  • Managing Director, Royalty Private Credit with two decades of healthcare investment and advisory experience 
  • Former Managing Director, Oppenheimer; Head of Medtech and Life Science & Tools practices 
  • Prior roles at BTIG, KKR, DRI Capital, and Cowen & Co. focused on healthcare royalty and finance 
  • Ph.D. and M.S. in Chemical Engineering, Columbia University; B.S., The Cooper Union 
Bob Davidson 

Bob Davidson 

Bob Davidson  headshot

Bob Davidson 

  • Founder of Davidson & Associates; acquired Blizzard Entertainment, led landmark sale, and launched Math Blaster™ 
  • Chairman and Co-Founder, Spree AI; pioneering AI-driven fashion retail technology 
  • Philanthropist and author; founded Davidson Academy for profoundly gifted youth, award-winning education advocate 
  • Degrees from Purdue (BS), George Washington (JD), UCLA (MBA); honorary doctorate, University of Nevada 
Uri Litvak

Uri Litvak

Uri Litvak headshot

Uri Litvak

  • Managing Partner, Litvak Law Groups 
  • Former Assistant General Counsel, AIG; Director and Legal Counsel, Cendant Corporation 
  • Nearly three decades of experience in the areas of M&A, corporate law, securities, and corporate finance 
  • JD, University of Miami; BA, New York University, magna cum laude 
Phil Trad

Phil Trad

Phil Trad headshot

Phil Trad

  • Former President/General Counsel at CEATS, Krystal Digital; expertise in patent development and FDA approvals 
  • Represented clients including General Electric Corporation, NBC Studios, Black and Decker, Budget Rent-A-Car, Hertz and MGM Corporation 
  • Experienced business litigator in California since 1978, specializing in insurance defense and corporate law  
  • JD, Western State University College of Law; BA, California State University, Fullerton 

“GATC’s AI has enabled this first-of-a-kind combination of financing protected by insurance in case the clinical trial is not successful. The early response from biotech companies and large brokerage firms for this product has exceeded our expectations which represents the pent-up demand for this innovative financing program.”

Ben Canagaretna

Global Managing Director of Acrisure Re Corporate Advisory & Solutions

Forward thinking and 
future-focused

We understand who we serve. Our partners are pioneers who see a problem and try to find a solution. And so do we. We step up to the challenge with discipline and imagination.

Unmatched predictive power

Break the cycle of risk, cost, and delay. Bring scientific integrity and financial confidence to every decision. GATC Health’s predictive analytics aren’t just trusted by scientists; they’re relied upon by some of the largest institutions in the world. Whether you’re an investor, insurer, or developer, GATC Health helps you make smarter, lower-risk choices.

86%
Sensitivity
Outperforms industry average by 20x in early-stage drug success predictions
10-18
months
to progress through pre-clinical